P73 G4C14-to-A4T14 polymorphisms are positively correlated with triple-negative breast cancer in southwestern China

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Zhou, Xin ^a  

^a Chongqing Cancer Institute   (China)

Author keywords

Breast cancer; Chemosensitivity; p73; Polymorphism

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P73; DNA BINDING PROTEIN; NUCLEAR PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ADULT; ARTICLE; AXILLARY LYMPH NODE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMOSENSITIVITY; CHI SQUARE TEST; CHINA; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STUDENT T TEST; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; AGED; BREAST TUMOR; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHINA; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84874170178     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0515-x     Document Type: Article

References (46)

1. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809-19.
2. Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560-4.
3. Jost CA, Marin MC, Kaelin WG Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 1997;389:191-4.
4. Mai M, Yokomizo A, Qian C, et al. Activation of p73 silent allele in lung cancer. Cancer Res. 1998;58:2347-9.
5. Yokomizo A, Mai M, Tindall DJ, et al. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene. 1999;18:1629-33.
6. Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumors. Nature. 2000;404:99-103.
7. Takahashi H, Ichimiya S, Nimura Y, et al. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res. 1998;58:2076-7.
8. Rufini A, Agostini M, Grespi F, et al. p73 in Cancer. Genes Cancer. 2011;2:491-502.
9. Peters MA, Janer M, Kolb S, et al. Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. Prostate. 2001;48:292-6.
10. Li Q, Athan ES, Wei M, et al. TP73 allelic expression in human brain and allele frequencies in Alzheimer's disease. BMC Med Genet. 2004;5:14-22.
11. Chen X, Sturgis EM, Etzel CJ, et al. p73 G4C14-to-A4T14 polymorphism and risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never smokers and never drinkers. Cancer. 2008;113:3307-14.
12. De Feo E, Persiani R, La Greca A, et al. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. Mutat Res. 2009;675:60-5.
13. Umar M, Upadhyay R, Khurana R, et al. Role of p53 and p73 genes polymorphisms in susceptibility to esophageal cancer: a case control study in a northern Indian population. Mol Biol Rep. 2012;39:1153-62.
14. Deng B, Liu F, Wei Y, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population. Tumour Biol. 2013;34:293-9.
15. Wang Z, Sturgis EM, Guo W, et al. Association of combined p73 and p53 genetic variants with tumor HPV16-positive oropharyngeal cancer. PLoS ONE. 2012;7:e35522.
16. Ryan BM, McManus R, Daly JS, et al. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer. 2001;85:1499-503.
17. Hu Z, Miao X, Ma H, et al. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer. 2005;114:455-60.
18. Zhou X, Wu C. Association of p73 polymorphisms with genetic susceptibilities to breast cancer: a case-control study [J]. Med Oncol. 2012;29:3216-21.
19. Huang XE, Hamajima N, Katsuda N, et al. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer. 2003;10:307-11.
20. Choi JE, Kang HG, Chae MH, et al. No association between p73 G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean population. Biochem Genet. 2006;44:543-50.
21. Hamajima N, Matsuo K, Suzuki T, et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett. 2002;181:81-5.
22. Wang L, Gao R, Yu L. Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk. Mol Biol Rep. 2012;39:1731-8.
23. Yu XJ, Fang F, Xie J, et al. Relationship between TP73 polymorphism (G4C14-A4T14) and cancer risk: a meta-analysis based on literatures. Gene. 2011;484:42-6.
24. Liu F, Liu L, Li B, et al. p73 G4C14-A4T14 polymorphism and cancer risk: a meta-analysis based on 27 case-control studies. Mutagenesis. 2011;26:573-81.
25. Hu Y, Jiang L, Zheng J, et al. Association between the p73 exon 2 G4C14-to-A4T14 polymorphism and cancer risk: a meta-analysis. DNA Cell Biol. 2012;31:230-7.
26. Thorleifsson G, Walters GB, Hewitt AW, et al. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nat Genet. 2010;42:906-9.
27. Shi Y, Xiang P, Li L, Shen M. Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population. Forensic Sci Int. 2011;207:183-7.
28. Millis MP. Medium-throughput SNP genotyping using mass spectrometry: multiplex SNP genotyping using the iPLEX-Gold assay. Methods Mol Biol. 2011;700:61-76.
29. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721-8.
30. Wolff A, Hammond M, Schwartz J, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43.
31. Wolff A, Hammond M, Schwartz J, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-45.
32. Lee KE, Hong YS, Kim BG, et al. p73 G4C14 to A4T14 polymorphism is associated with colorectal cancer risk and survival. World J Gastroenterol. 2010;16(35):4448-54.
33. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
34. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26:778-85.
35. Haber DA, Fearon ER. The promise of cancer genetics. Lancet. 1998;351:1-8.
36. Pfeifer D, Arbman G, Sun XF. Polymorphism of the p73 gene in relation to colorectal cancer risk and survival. Carcinogenesis. 2005;26:103-7.
37. Arfaoui AT, Kriaa LBM, El Hadj OEA, et al. Association of a p73 exon 2 GC/AT polymorphism with colorectal cancer risk and survival in Tunisian patients. Virchows Arch. 2010;457:359-68.
38. Liu L, Wu C, Wang Y, et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol. 2011;6:1793-800.
39. Lööf J, Pfeifer D, Adell G, et al. Significance of an exon 2 G4C14-to-A4T14 polymorphism in the p73 gene on survival in rectal cancer patients with or without preoperative radiotherapy. Radiother Oncol. 2009;92:215-20.
40. Li H, Yao L, Ouyang J, et al. Association of p73 G4C14-to-A4T14(GC/AT) polymorphism with breast cancer survival. Carcinogenesis. 2007;28:372-7.
41. Rakha EA, Chan S. Metastatic triple-negative breast cancer. Clin Oncol (R Coll Radiol). 2011;23:587-600.
42. Irwin MS, Kondo K, Marin MC, et al. Chemosensitivity linked to p73 function. 2003;3:403-10.
43. Yuan P, Miao XP, Zhang XM, et al. Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms. Zhonghua Zhong Liu Za Zhi. 2006;28:107-10.
44. Liu K, Jiang L, Zhou X. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 with the response of human lung adenocarcinoma cell lines to chemotherapy. Cell Biol Int. 2010;34:185-8.
45. Tiwary R, Yu W, Sanders BG, et al. α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73 [J]. Breast Cancer Res. 2011;13:R1.
46. Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin [J]. Cancer Res. 2010;70:7970-80.